LearnGlossaryMarketStocksSuperinvestorsSign in

TBPH

Theravance Biopharma Inc

Healthcare · $883M market cap

Verdict

We can't put a fair value on TBPH right now. It has fewer than 5 profitable years and uneven cash flow, not enough history to project from yet.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-3.1% a year✗
Sales growth9.6% a year✗
Free cash flow growth—?
Return on invested capital-10.7%✗

Follow TBPH

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Sep 23, 2026. How the Payback Price works